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A B S T R A C T
Purpose: Mutations in PCDH19, encoding protocadherin 19 on chromosome X, cause familial epilepsy
and mental retardation limited to females or Dravet-like syndrome. We wished to explore the causative
role of PCDH19 gene (Xq22) in female patients with epilepsy, from Southern Italy.
Methods: Direct sequencing of PCDH19 gene was conducted in 31 unrelated female patients with early
onset (<1 year of age) epilepsy and a wide spectrum of phenotypes including febrile seizures, focal and
generalized forms, with either sporadic or familial distribution.
Results: We identiﬁed two de novo heterozygous novel mutations of PCDH19 gene (p.Arg550Pro,
Ile508ProfsX59) in two of 31 unrelated female patients. We also identiﬁed a novel silent mutation
p.Ser856=.
Conclusions: The present ﬁndings conﬁrm that PCDH19 is a major causative gene for infantile onset
familial or sporadic epilepsy in female patients with or without mental retardation.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy and mental retardation limited to female (EFMR,
MIM# 300088) is an X-linked disorder due to mutations in the
PCDH19 gene, located on chromosome X and encoding the
protocadherin 19. This disorder presents an unusual mode of
inheritance as only females with heterozygous mutations are
affected whereas males with hemizygous mutations are unaffect-
ed.1–4 A plausible explanation of this peculiar pattern of
inheritance is that the pathogenic mechanism underlying PCDH19
mutations results from cellular interference, so only subjects with
a combination of PCDH19-negative and PCDH19 wild-type cells
develop symptoms.5 This mechanism of cellular interference is
supported by the presence of affected mosaic males.
The protocadherin19 is a transmembrane protein that belongs
to the cadherin family of calcium-dependent-cell adhesion
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extracellular domain,1,5,7–12 but other exons may be also
involved.10Missense and truncating mutations have been reported
as well as deletions at the PCDH19 gene.8,10,13 Most patients with
PCDH19 mutations are sporadic or belong to families with few
affected female patients, making the recognition of the inheritance
pattern difﬁcult. Moreover, whole gene deletions or partial
deletion of PCDH19 gene were found in sporadic female patients,10
suggesting that submicroscopic chromosomal abnormalities
should be also investigated in patients negative for PCDH19
mutations.
The aim of the present study was to identify PCDH19
mutations in a series of 31 female patients with early onset
(<1 year of age) epilepsy from Southern Italy. Multiplex
ligation-dependent probe ampliﬁcation (MLPA) was also applied
to examine whether microdeletions and duplications of the
PCDH19 gene may occur in such patients that were negative for
PCDH19 mutations.
2. Subjects
We collected 31 Italian females with a wide spectrum of
phenotypes including mainly DS patients, with febrile or afebrileserved.
Table 1
Summary of the clinical and genetic data of three female patients carrying de novo PCDH19 mutations.
Patient no. Age at
exam
Age at
onset
Type of the
ﬁrst seizure
Type of seizures SE SZ in
cluster
Pho
sen.
Language Intellectual
disability
PCDH19 de novo
mutations
1 8y 7 m FS Febrile and afebrile
sGTCS Absences
Yes Yes No Normal Severe with autistic features Ile508ProfsX59
2 9y 8 m FS Febrile and afebrile
sGTCS Absences
Yes Yes No Normal Severe with autistic features Arg550Prof
3 9y 9 m FS sGTCS Absences Yes Yes No Normal Severe with autistic features Ser856=
y = years; m = months; FS: febrile seizure; sGTCS = secondarily generalized tonic clonic seizures.
Fig. 1. Three different heterozygous de novo novel variants of PCDH19 gene. (A) Sequence electropherograms of the mutations identiﬁed (c.2568C > T/p.Ser856=,
c.1522_1528del/p.Ile508ProfsX59, c.1649G > C/p.Arg550Pro). (B) Alignment of the regions surrounding the mutations (indicated in the box) in orthologous and paralogous
proteins, showing the high conservation of each affected amino acid in vertebrates and in the delta protocadherin paralogous genes.
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patients had an age at onset of epilepsy during the ﬁrst year of life.
The local Ethics Committee approved the study, and written
informed consent was obtained from all individuals involved.
3. Methods
Genomic DNA was extracted from peripheral blood by standard
methods. The presence of mutations of the SCN1A gene was
previously excluded by sequencing analysis and MLPA method
(SALSA MLPA P137-B2 SCN1A probemix). The primers ﬂanked all
5 exons and intron–exon boundaries of PCDH19 (Entrez Gene,
Gene ID: 57526, Accession Number: EF676096.1) were designed
using the web primer SGD (Saccharomyces Genome Database). The
puriﬁed PCR products were sequenced on an ABI 3130 XL AVANT
sequencer (Applied Biosystems and Life Technologies, Carlibad, CA,
USA). The new identiﬁed PCDH19 mutations were checked in a
control population of 200 ethnically matched controls.
We used the Exome Variant Server (http://evs.gs.washingto-
n.edu/EVS/) to ascertain that the PCDH19 identiﬁed was not
present in variants databases. We assessed amino acid conserva-
tion in orthologs using UCSC (http://genome.ucsc.edu). The
pathogenic potential of the identiﬁed variant was predicted using
Mutation Taster Server (http://www.mutationtaster.org).
In the present study, MLPA analysis was also performed to
detect PCDH19 rearrangements. The probes used for MLPA
reaction were designed to hybridize to each region of the exons.4. Results
A total of three different variants, all novels, were identiﬁed
at the heterozygous state in 3 out of 31 (9.6%) female patients
(Table 1, Fig. 1). Two heterozygous mutations consisted of a
frameshift mutation p.Ile508ProfsX59 (c.1522_1528delATCAATC)
and a missense mutation p.Arg550Pro (c.1649G > A) respectively,
which were located in the large exon 1. In the third patient, we
identiﬁed a novel silent mutation p.Ser856 = (c.2568C > T) that
was located in the exon 4. The corresponding mutations were
absent in both parents of all three affected members, indicating
that they always arose de novo. Both missense variants affected
amino acids of the extracellular domain of protocadherin
19. All the three novel variants occurred at reasonably conserved
amino acid (Fig. 1). The identiﬁed PCDH19 alterations were not
found in a control population of 200 healthy Italian individuals.
5. Discussion
The results of this study indicate that PCDH19 mutations are a
relatively frequent cause of epilepsy in female patients from
Southern Italy (6.4% (2/31) carried PCDH19 mutations) with early
onset epilepsy before one year of age. This relatively high rate of
PCDH19 mutations probably comes from the analysis of a
particular and rather speciﬁc phenotype where the likelihood of
ﬁnding PCDH19 mutation is higher than just selecting female
patients with early onset epilepsy and with a broader phenotype.
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PCDH19 mutations was severe with early onset seizures, which
generally occurred in cluster and were especially likely to occur
with fever. Of note, these clinical features are very similar to those
of previously reported patients carrying PCDH19 mutations:
clusters of seizures during febrile illnesses. Conversely, they
differed slightly from classical DS phenotype, as none of them have
myoclonic jerks/atypical absences.
Cadherins play a crucial role in neuronal cell adhesion. In fact,
the Arg550Pro and Ile508ProfsX59 mutations identiﬁed in this
study fall in the large exon 1 of the gene, corresponding to the
extracellular cadherin domains of protocadherins that are crucial
for normal function. These mutations affect residues belonging to
conserved calcium binding activity or alter the PCDH19 extracel-
lular structure. Amino acid substitutions in the cytoplasmic
domain appear to have less or no deleterious effects on protein
function. The novel heterozygous silent mutation, p.Ser856=, was
located in exon 4. In exons 3–5 a relatively small number of only
truncating mutations are found. In the literature, indeed, four
distinct mutations in the exon 4 (framshift, nonsense, and splicing
site mutation) were already reported.7–9 The exon 4 encodes to the
intracellular cadherin domains of the PCDH19 protein. It interacts
with cytoskeleton and with signal transmission pathway. Although
this alteration is not located in on EC domain, the cytoplasmic
domains of protocadherins do show a high level of conservation.7
Previous studies claimed that chromosomal rearrangements
may occur, so screening of PCDH19 should always include a
speciﬁc method to search for rearrangements in addition to direct
sequencing of the whole coding sequence. Nonetheless, we failed
to depict chromosomal rearrangements involving the PCDH19
gene in our series.
These two novel mutations are damaging according to
prediction program (Mutation Taster) and suggest a loss of
function of the protein in both cases. The affected amino acids
are extremely conserved in the evolution of the PCDH19
homologues, suggesting an important functional role.
In summary, we have identiﬁed two novel mutations in the
PCDH19 gene further conﬁrming that it is a major causative gene
for infantile-onset familial or sporadic epilepsy in female patients
with or without mental retardation. Genotype–phenotype corre-
lation was largely consistent with the previous studies, a moleculardiagnosis results important for patient’s management and genetic
counseling.
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